DISEASE INDICATIONS: Atopic Dermatitis

MANUFACTURER: Leo Pharma

USAGE: Subcutaneous

MEDICINE APPROVED BY:

Food and Drug Administration (FDA)

Adbry is a medication that helps treat moderate-to-severe eczema. It is an injectable drug that blocks the activity of IL-13, which is a cytokine responsible for inflammation in eczema. A healthcare provider or trained patient/caregiver should administer the recommended dosage of 300 mg subcutaneously. Clinical studies have shown improvement in the symptoms of eczema.